Archer-Daniels-Midland Co (ADM) Stock News

Rosen Law Firm reminds investors of the August 10, 2026 deadline to join a securities class action lawsuit against ADMA Biologics. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls that artificially inflated revenue during the class period from August 9, 2024 to March 25, 2026.

ADMA Biologics is facing a securities fraud class action lawsuit alleging misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report in March 2026 revealed channel stuffing and improper accounting practices, causing the stock to plunge 31.6% over two trading days. The lawsuit covers the period from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.

ADMA Biologics is facing a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth in 2025 was artificially inflated, with actual revenue declining 3% when adjusted for extended payment terms. The stock declined over 16% following the report, and an additional 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by Monday, August 10, 2026.

Class action lawsuits have been filed against four publicly-traded companies for alleged securities fraud. Futu Holdings faces allegations of non-compliance with Chinese regulatory requirements, First Solar allegedly overstated its ability to manage tariff impacts, Black Rock Coffee Bar allegedly misrepresented its expansion strategy and cannibalization effects, and ADMA Biologics allegedly engaged in undisclosed related party transactions and channel stuffing. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against ADMA Biologics, Inc. following allegations of channel stuffing and undisclosed related party transactions. Culper Research reported that ADMA induced distributors to stock excess inventory through rebates and extended payment terms to artificially inflate revenue growth. The stock fell 29.1% on the news, and investors have until August 10, 2026 to file a lead plaintiff motion.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. alleging misrepresentations concerning financial condition, revenue recognition, and undisclosed related-party transactions. The lawsuit covers the period from August 9, 2024 to March 25, 2026. Following a short-seller report by Culper Research on March 24, 2026 revealing channel stuffing and undisclosed distributor Genesis BioPharma, ADMA's stock plummeted 31.6% over two trading days, with further declines following a rating downgrade.

Kahn Swick & Foti, LLC announces a class action securities lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. The application deadline to request lead plaintiff status is August 10, 2026.

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics (NASDAQ: ADMA) alleging the company artificially inflated stock value through misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A Culper Research short-seller report in March 2026 revealed channel stuffing and undisclosed distributor Genesis BioPharma, causing the stock to plunge 31.6% over two trading days, with further declines following a Cantor Fitzgerald downgrade.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

Rosen Law Firm announces a securities class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls. The deadline to serve as lead plaintiff is August 10, 2026.

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements about revenue growth through channel stuffing and undisclosed related party transactions. A Culper Research report claimed ADMA's reported 20% growth in 2025 was actually -3% when adjusted for extended payment terms. The stock declined over 16% following the report, and another 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.

ADMA Biologics faces a securities fraud class action lawsuit after its stock plummeted following Culper Research's allegations of channel stuffing. The company allegedly inflated its 2025 revenue growth from -3% to +20% by inducing distributors to overstock its flagship product ASCENIV through rebates and extended payment terms. The stock dropped 29% cumulatively following the March 2026 revelations and subsequent analyst downgrades.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly misrepresenting its financial condition, engaging in channel stuffing, undisclosed related-party transactions, and lacking adequate internal controls. The allegations were exposed by a Culper Research short-seller report on March 24, 2026, causing the stock to plunge 31.6% over two trading days. Investors with substantial losses are urged to contact Hagens Berman by the August 10, 2026 deadline to participate in the class action.

ADMA Biologics faces a securities class action lawsuit for allegedly failing to disclose material information between August 2024 and March 2026. The company is accused of undisclosed related party transactions, channel stuffing, inadequate internal controls, and making false statements about its business operations and prospects. Investors with losses exceeding $100,000 have until August 10, 2026 to file lead plaintiff applications.

Rosen Law Firm announces a securities class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. The lead plaintiff deadline is August 10, 2026.

ADMA Biologics faces a class action securities fraud lawsuit after Culper Research alleged channel stuffing and undisclosed related party transactions. The company allegedly induced distributors to stock excess inventory using rebates and extended payment terms to artificially inflate revenue growth. ADMA's stock fell 29.1% following the report. The deadline to file a lead plaintiff motion is August 10, 2026.

A securities fraud class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) alleging the company artificially inflated stock value through misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A March 2026 short-seller report exposed channel stuffing and undisclosed distributor Genesis BioPharma, causing the stock to plunge 31.6% over two trading days. Investors with substantial losses are urged to contact Hagens Berman by the August 10, 2026 lead plaintiff deadline.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased shares between August 9, 2024 and March 25, 2026 can join the lawsuit with a deadline of August 10, 2026.

A securities fraud class action has been filed against ADMA Biologics (NASDAQ: ADMA) for allegedly making false statements about its financial condition and business practices. The lawsuit claims the company engaged in undisclosed related-party transactions, channel stuffing, and lacked adequate internal controls. A Culper Research short-seller report in March 2026 exposed these allegations, causing the stock to plunge 31.6% over two trading days, with further declines following an ADMA response and analyst downgrade.

Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges ADMA engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls, resulting in materially false statements about the company's business and operations.

Pomerantz Law Firm has filed class action lawsuits against ADMA Biologics, Lucid Group, and Nano-X Imaging, alleging securities fraud and unlawful business practices. ADMA's stock declined significantly following a short report alleging channel stuffing and inflated revenue figures, with additional losses after a downgrade from Cantor Fitzgerald.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth. A short-seller report claimed the company engaged in channel stuffing and used an undisclosed related party distributor, with actual 2025 revenue declining 3% versus reported 20% growth. The stock fell 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.

Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls.

ADMA Biologics faces a class action securities fraud lawsuit alleging the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth. A March 2026 report revealed ADMA induced distributors to stock excess inventory through rebates and extended payment terms, resulting in a 29.1% stock price decline. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, with an August 10, 2026 deadline to file a lead plaintiff motion.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

Rosen Law Firm reminds investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of the August 10, 2026 deadline to join a securities class action lawsuit. The firm alleges that ADMA made false statements regarding undisclosed related-party transactions, channel stuffing practices, inadequate internal controls, and misleading revenue representations during the period from August 9, 2024 to March 25, 2026.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

A class action lawsuit has been filed against ADMA Biologics for alleged securities fraud. Culper Research published a report claiming the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The allegations led to a 29.1% stock price decline on March 25, 2026. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file a lead plaintiff motion by August 10, 2026.